AOP-208
Pharmaceutical compound
From Wikipedia, the free encyclopedia
AOP-208, also known as LB-208, is a selective serotonin 5-HT1B receptor antagonist which is under development for the treatment of lymphoma, solid tumors, acute myeloid leukemia, and myelodysplastic syndromes.[1][3][2] It is taken orally.[1][2] The drug is being developed by AOP Orphan Pharmaceuticals AG and Leukos Biotech.[1][3] As of October 2024, it is in phase 1 clinical trials for lymphoma and solid tumors and is in the preclinical research stage of development for acute myeloid leukemia and myelodysplastic syndromes.[1][3] The chemical structure of AOP-208 does not yet appear to have been disclosed.[1]
Other namesAOP208; LB-208; LB208
| Clinical data | |
|---|---|
| Other names | AOP208; LB-208; LB208 |
| Routes of administration | Oral[1][2] |
| Drug class | Serotonin 5-HT1B receptor antagonist |
